Abstract 1117P
Background
Skin melanoma, particularly acral melanoma, is known for its poor prognosis, often exacerbated by infections and chronic ulcers. Recent research has highlighted the significant role of intratumoral microbiota in various cancers, but its impact remains less understood in Chinese patients with skin melanoma. This study aims to investigate the intratumoral microbiota in melanoma among this group and explore its potential influence on disease progression.
Methods
One hundred melanoma tissue samples from stage III/IV skin or acral melanoma patients at Sun Yat-sen University Cancer Center, collected between 2015 and 2021, were retrospectively collected and underwent LPS immunohistochemistry (IHC). Kaplan-Meier analysis was used to assess the relation of LPS expression and patients overall survival. Microbial diversity was analyzed through 16S rRNA sequencing. Spatial transcriptomics was applied to map LPS-positive and LPS-negative regions, enabling the exploration of transcriptional differences and cell distributions.
Results
Patients with high LPS levels exhibited a median overall survival (mOS) of 13.7 months (95% CI, 10.6–16.9), which was shorter compared to those with low LPS levels, who had not yet reached median survival. Analysis of tumor microbiota revealed significant diversity, with high proportions of Bifidobacterium, Vibrio, Bacillus, Clostridium sensu stricto, and Pseudomonas, among which Pseudomonas was the dominant genus. Spatial transcriptomic analysis of LPS-positive melanoma tissues showed an increased proportion of M2 macrophages and a decreased proportion of effector T cells. Gene set enrichment analysis (GSEA) further indicated the activation of epithelial-mesenchymal transition (EMT) pathways.
Conclusions
High levels of microbiota within melanoma tissues are correlated with poor overall survival and may facilitate tumor immune evasion and metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1101P - Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Presenter: Mario Mandalà
Session: Poster session 04
1102P - Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
Presenter: Allison Betof Warner
Session: Poster session 04
1103P - Real-world efficacy of relatlimab and nivolumab in advanced or resectable melanoma
Presenter: Lilit Karapetyan
Session: Poster session 04
1104P - Early time-point <sup>18</sup>F-FDG-PET/CT at week four (W4) as a prognostic biomarker of survival in metastatic melanoma (mM) patients (pts) on immunotherapy
Presenter: Nezka Hribernik
Session: Poster session 04
1105P - Predicting the outcomes of advanced cutaneous melanoma cases following discontinuation of immune checkpoint inhibition
Presenter: Ka-won Noh
Session: Poster session 04
1106P - NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma
Presenter: Mora Guardamagna
Session: Poster session 04
1107P - Characteristics and quality of life of nine-year survivors from 312 patients with metastatic melanoma treated with pembrolizumab
Presenter: Jessica Hassel
Session: Poster session 04
1108P - Impact of quantitative imaging of all disease on the prognostic value of <sup>18</sup>F-FDG PET/CT in patients treated with immunotherapy for metastatic melanoma
Presenter: Robert Jeraj
Session: Poster session 04
1109P - Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors
Presenter: Eva Ellebaek
Session: Poster session 04
1110P - Follow-up brain imaging in patients with melanoma brain metastasis and immune checkpoint inhibitors
Presenter: Imren Ozdamar
Session: Poster session 04